Evidence map›Paper›PMID 37894370›Full record

ArticleCancers2023

Evening Primrose Extract Modulates TYMS Expression via SP1 Transcription Factor in Malignant Pleural Mesothelioma.

Małgorzata Chmielewska-Kassassir, Katarzyna Sobierajska, Wojciech M Ciszewski, Jakub Kryczka, Andrzej Zieleniak, Lucyna A Wozniak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Małgorzata Chmielewska-KassassirDepartment of Structural Biology, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0003-1440-2222
Katarzyna SobierajskaDepartment of Molecular Cell Mechanisms, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.ORCID 0000-0003-3510-0098
Wojciech M CiszewskiDepartment of Molecular Cell Mechanisms, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.ORCID 0000-0001-6251-6043
Jakub KryczkaInstitute of Medical Biology, Polish Academy of Sciences, Lodowa 106, 93-232 Lodz, Poland.ORCID 0000-0002-5719-4139
Andrzej ZieleniakDepartment of Structural Biology, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0002-7353-4578
Lucyna A WozniakDepartment of Structural Biology, Medical University of Lodz, Żeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0002-9966-1807
Medical University of Lodz · PLInstitute for Medical Biology · PL

Funding

National Science Center 2015/19/N/NZ3/01497
6 · The paper itself

Abstract

purposeTo determine the mechanism of EPE in downregulating TYMS in MPM cancer.

methodsThe TYMS mRNA expression with epithelial-to-mesenchymal transition biomarkers and nuclear factor SP1 was assessed using the GEO database in a data set of MPM patients (GSE51024). Invasive MPM cell lines were in vitro models for the investigation of TYMS expression after EPE treatment. The

resultsIn MPM patients, a positive correlation of overexpressed TYMS with mesenchymal TWIST1, FN1 and N-cadherin was observed. EPE and its major components, gallic and ellagic acid (GA and EA, respectively), downregulated TYMS in invasive MPM cells by interacting with particular SP1 motifs on the

conclusionEPE components reduced TYMS expression by occupation of SP1 motifs on the

Indexed as

epithelial-to-mesenchymal transitionevening primrose extractmalignant pleural mesotheliomaspecificity protein 1 nuclear factorthymidylate synthase

Identifiers

PMID37894370
PMCPMC10605291
OpenAlexW4387668811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.